Resverlogix Corp RFS-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:02 AM CET
0.66UNCH (UNCH)
52 week range
0.34 - 0.91

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.66
  • 52 Week High0.91
  • 52 Week High Date02/24/20
  • 52 Week Low0.34
  • 52 Week Low Date06/09/20
  • Market Cap168.72M
  • Shares Out233.99M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-25.84

RATIOS/PROFITABILITY

  • EPS (TTM)0.01
  • P/E (TTM)66.00
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Resverlogix Corp News

There is no recent news for this security.

Latest RFS-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of...
Donald McCaffrey
Chairman
A. Brad Cann
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada